Wound healing products company Aroa Biosurgery (ARX: $0.86) continues to deliver consistent and strong top-line growth. Cash receipts in the June quarter were NZ$13.9 million (up 162% over the PCP). Net cash outflow was NZ$1.3 million from operations and investment in equipment, down from NZ$3.7 million in the PCP and down from NZ$6.5 million in the previous quarter.

The strong performance in the June quarter included a large shipment of product to the company's distributor, TelaBio, in the March quarter. The company is maintaining its revenue guidance of NZ$51 - NZ$55 million for this financial year (which ends 31 March 2023).

Cogstate (CGS: $1.83) has delivered a stunning year result for FY2022 with sales (contracts signed) of US$82.5 million. Revenue (unaudited), which trails the signing of contracts in a growth phase, was US$45 million, up 38% to the previous corresponding period (PCP).

Patrys (PAB: $0.023) has received some delays over the last two years to making its novel antibody drug candidate, PAT-DX1. However the path to clinical studies now appears in sight with a successful manufacturing run exceeding previous product yield expectations.

Imugene (IMU: $0.225) has released final overall survival data from its Phase Ib/II HER-Vaxx study in 36 patients with advanced gastric cancer with tumours that overexpressed the HER2 receptor.

Radiopharm Theranostics (RAD: $0.16) has in-licensed an additional targeting agent from Case Western Reserve University (CWRU) in the US.

The peptide licensed targets a fragment of a receptor found only on tumour cells and not in healthy tissue, called PTPµ. The peptide has been found, in preclinical studies, to recognise not only the main tumour but also small tumour metastases.

Imricor Medical Systems (IMR: $0.115) listed on the ASX in 2019 at $0.83 per share raising $13 million. The company was formed in 2006 in the US and is pioneering cardiac ablation treated specifically through the guidance of MRI. Traditional ablation procedures are conducted using fluoroscopy and x-ray imaging.

There are multiple advantages in using MRI to help guide the procedure, most notably the better imaging quality that can be achieved compared to x-ray. This results in arguably better ablation outcomes, less repeat procedures and shorter treatment periods. Efficacy of the ablation procedures involves inserting an ablation catheter through the veins or arteries to correct irregular electrical signals in the heart. Other safety benefits for patients and surgeons come from not using x-ray images.

Antibody development company Patrys (PAB: $0.021) has announced the publication of some new and important data around its rare portfolio of compounds.

CEO of Radiopharm Theranostics (RAD: $0.185), Riccardo Canevari, believes that the next big platform in oncology, following immunotherapy and cell therapies, will be radiopharmaceuticals.

Canevari highlighted the said the approval of Lutathera (in 2018) from Novartis (where Canevari was working at the time), for the treatment of neuroendocrine tumours and the more recent approval this year of Pluvicto (also from Novartis) as key events for the sector. Lutathera achieved a stunning efficacy result in its pivotal trial achieving a hazard ratio of 0.21, meaning a 79% risk reductio of disease progression or death. For Pluvicto, reaching primary and secondary endpoints in prostate cancer was a game changer.

By 2027 the sales of biologics are predicted to surpass the aggregate sales of small molecule drugs, with US$120 billion more sales and making up 55% of all drug sales. This is a positive aspect for Patrys (PAB: $0.022), an antibody therapeutics company, according to CEO James Campbell. However, small molecule drug sales are still expected to increase by around 50% over this period driven by CNS therapy product sales.

During the pandemic, Dimerix (DXB: $0.17) was very pleased to have been able to complete two Phase II kidney disease studies. The company has now moved to a Phase III program in FSGS (kidney disease) involving 75 sites spread across 12 countries, including in the US where the company recently gained FDA approval (IND) to commence its study there as well. The first patient was treated in this study this week.

Dimerix CEO Nina Webster said that sclerotic kidney disease is a progressive three mechanism cycle that results in an acceleration of the disease as it progresses to end stage kidney failure. The drugs currently on the market all focus on the first mechanism of this disease by reducing hypertension across the bloodstream.